These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 23620309)

  • 1. Response to the letter "nonalcoholic fatty liver disease may be associated with coronary artery disease complexity".
    Agaç MT; Korkmaz L; Cavusoglu G; Karadeniz AG; Agaç S; Bektas H; Erkan H; Varol MO; Vatan MB; Acar Z; Mentese U; Celik S
    Angiology; 2013 Nov; 64(8):641. PubMed ID: 23620309
    [No Abstract]   [Full Text] [Related]  

  • 2. Nonalcoholic Fatty liver disease may be associated with coronary artery disease complexity.
    Balta S; Demirkol S; Ay SA; Kurt O; Unlu M; Celik T
    Angiology; 2013 Nov; 64(8):639-40. PubMed ID: 23564020
    [No Abstract]   [Full Text] [Related]  

  • 3. Association between nonalcoholic fatty liver disease and coronary artery disease complexity in patients with acute coronary syndrome: a pilot study.
    Agaç MT; Korkmaz L; Cavusoglu G; Karadeniz AG; Agaç S; Bektas H; Erkan H; Varol MO; Vatan MB; Acar Z; Mentese U; Celik S
    Angiology; 2013 Nov; 64(8):604-8. PubMed ID: 23439214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease.
    Wong VW; Wong GL; Yip GW; Lo AO; Limquiaco J; Chu WC; Chim AM; Yu CM; Yu J; Chan FK; Sung JJ; Chan HL
    Gut; 2011 Dec; 60(12):1721-7. PubMed ID: 21602530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved management of patients after acute coronary syndrome: using nonalcoholic fatty liver disease fibrosis score and ezetimibe?
    Pitha J
    Int J Cardiol; 2018 Nov; 270():260-261. PubMed ID: 30017528
    [No Abstract]   [Full Text] [Related]  

  • 6. Letter: TNFα inhibitors and prevalence of fatty liver disease in chronic inflammatory diseases.
    Sartini A; Leonardi F; Gitto S; Di Girolamo M; Villa E
    Aliment Pharmacol Ther; 2015 Aug; 42(4):489. PubMed ID: 26179764
    [No Abstract]   [Full Text] [Related]  

  • 7. Nonalcoholic fatty liver disease in pediatric patients--a problem that is "enormous" and "growing"!
    Rosenthal P
    JPEN J Parenter Enteral Nutr; 2012 Jan; 36(1 Suppl):7S-8S. PubMed ID: 22237882
    [No Abstract]   [Full Text] [Related]  

  • 8. Nonalcoholic fatty liver in nondiabetic patients with acute coronary syndromes.
    Boddi M; Tarquini R; Chiostri M; Marra F; Valente S; Giglioli C; Gensini GF; Abbate R
    Eur J Clin Invest; 2013 May; 43(5):429-38. PubMed ID: 23480577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between nonalcoholic fatty liver disease and coronary artery disease.
    Vilar CP; Cotrim HP; Florentino GS; Barreto CP; Florentino AV; Bragagnoli G; Schwingel PA
    Rev Assoc Med Bras (1992); 2013; 59(3):290-7. PubMed ID: 23684211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonalcoholic fatty liver disease and cardiovascular disease risk.
    Brown TM
    Clin Gastroenterol Hepatol; 2012 Jun; 10(6):568-9. PubMed ID: 22387255
    [No Abstract]   [Full Text] [Related]  

  • 11. The cardiovascular link to nonalcoholic fatty liver disease: a critical analysis.
    Pacana T; Fuchs M
    Clin Liver Dis; 2012 Aug; 16(3):599-613. PubMed ID: 22824483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non alcoholic fatty liver disease increases the mortality from acute coronary syndrome: an observational study from Sri Lanka.
    Perera N; Indrakumar J; Abeysinghe WV; Fernando V; Samaraweera WM; Lawrence JS
    BMC Cardiovasc Disord; 2016 Feb; 16():37. PubMed ID: 26869052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonalcoholic fatty liver disease and hepatic cirrhosis: Comparison with viral hepatitis-associated steatosis.
    Haga Y; Kanda T; Sasaki R; Nakamura M; Nakamoto S; Yokosuka O
    World J Gastroenterol; 2015 Dec; 21(46):12989-95. PubMed ID: 26675364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Letter: systemic therapy for psoriasis could affect the prevalence of NAFLD.
    Tanoglu A; Beyazıt Y; Aydın E; Karagoz E
    Aliment Pharmacol Ther; 2015 Jun; 41(12):1301. PubMed ID: 25968152
    [No Abstract]   [Full Text] [Related]  

  • 15. [Nonalcoholic fatty liver disease and psoriasis].
    Rivera R; Vanaclocha F
    Actas Dermosifiliogr; 2010 Oct; 101(8):657-8. PubMed ID: 20965008
    [No Abstract]   [Full Text] [Related]  

  • 16. [Fatty liver and metabolic syndrome].
    Tor J; Muga R
    Med Clin (Barc); 2013 Sep; 141(6):252-3. PubMed ID: 23578845
    [No Abstract]   [Full Text] [Related]  

  • 17. [Update: epidemiology and pathophysiology of nonalcoholic fatty liver disease].
    Ogawa Y; Imajo K; Yoneda M; Nakajima A
    Nihon Shokakibyo Gakkai Zasshi; 2014 Jan; 111(1):14-24. PubMed ID: 24390255
    [No Abstract]   [Full Text] [Related]  

  • 18. Nonalcoholic fatty liver disease: a nutritional approach.
    Colak Y; Tuncer I; Senates E; Ozturk O; Doganay L; Yilmaz Y
    Metab Syndr Relat Disord; 2012 Jun; 10(3):161-6. PubMed ID: 22394108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-alcoholic fatty liver disease: an emerging liver disease in Taiwan.
    Hsu CS; Kao JH
    J Formos Med Assoc; 2012 Oct; 111(10):527-35. PubMed ID: 23089687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Nonalcoholic fatty liver disease as a risk factor of macroangiopahty in patients with type 2 diabetes].
    Trojak A; Idzior-Waluś B
    Przegl Lek; 2012; 69(12):1276-9. PubMed ID: 23750438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.